US-based Sparta Biomedical developed SBM-01 Biomimetic Implant for the treatment of chondral or osteochondral defects of the knee cartilage.
SBM-01 implant is a minimally invasive procedure for knee cartilage. It replaces the injured knee cartilage in patients consisting of single or several chondral or osteochondral defects in the knee.
Osteoarthritis (OA) is the most common joint disorders. Its features include irreversible particular cartilage degeneration causing joint pain, joint motion limitations, and the development of bony osteophytes. It is first treated with non-pharmacological management, visco supplementation injections, and anti-inflammatory medications.
SBM-01implant has a major impact on the patients who are suffering with knee cartilage damage. It acquires the properties of native cartilage by providing a smooth articulating surface. In addition, it also supports surrounding cartilage by stabilising subchondral bone, and thus preventing further growth of the disease.
U.S. Food and Drug Administration (FDA) grants breakthrough device designation for SBM-01 Biomimetic Implant for the treatment of knee cartilage damage.
